| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6099863 | JANSSEN PHARMS | Fast-dissolving galanthamine hydrobromide tablet |
Jun, 2017
(6 years ago) | |
| US6358527 | JANSSEN PHARMS | Fast-dissolving galanthamine hydrobromide tablet |
Jun, 2017
(6 years ago) | |
Razadyne is owned by Janssen Pharms.
Razadyne contains Galantamine Hydrobromide.
Razadyne has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Razadyne are:
- US6099863
- US6358527
Razadyne was authorised for market use on 28 February, 2001.
Razadyne is available in tablet;oral dosage forms.
Razadyne can be used as treatment of alzheimer's dementia.
The generics of Razadyne are possible to be released after 06 June, 2017.
Drugs and Companies using GALANTAMINE HYDROBROMIDE ingredient
Market Authorisation Date: 28 February, 2001
Treatment: Treatment of alzheimer's dementia
Dosage: TABLET;ORAL
How can I launch a generic of RAZADYNE before it's drug patent expiration?
More Information on Dosage
RAZADYNE family patents
